Israeli-Arab Chemist Represents Teva at European Peptide Conference
Translated & summarized from Alarab by baba
Chemical engineer Abdul Hamid Safi Al-Assadi represented Teva API at the TIDES Europe 2026 conference in Amsterdam. He presented research on an innovative peptide synthesis technique that uses fewer chemicals. Al-Assadi also leads a team developing new pharmaceutical manufacturing technologies and had a paper accepted for publication in the Journal of Peptide Science.
The story in 5 lines · by baba
- Abdul Hamid Safi Al-Assadi represented Teva API at the TIDES Europe 2026 conference in Amsterdam.
- Al-Assadi presented a poster on an innovative cyclic peptide synthesis technique using less chemicals.
- He leads Teva's Peptide R&D team, focusing on new manufacturing technologies.
- His research was accepted for publication in the Journal of Peptide Science.
- The conference is a major international event for peptide drug development and manufacturing.
Chemical engineer Abdul Hamid Safi Al-Assadi, a Peptide R&D Team Leader at Teva API, was selected to represent the company at the TIDES Europe 2026 conference in Amsterdam, Netherlands. The conference is a prominent international gathering focused on the development and manufacturing of peptide-based drugs.
Al-Assadi's selection highlights his scientific expertise and professional experience. He leads a research team dedicated to innovative pharmaceutical manufacturing technologies and improving production efficiency and quality. His work has culminated in the acceptance of a specialized research paper for publication this year in the Journal of Peptide Science.
At the conference, Al-Assadi presented a scientific poster detailing an innovative technique for forming chemical bonds in the synthesis of cyclic peptides. This method utilizes reduced amounts of chemicals, aiming to simplify manufacturing, decrease impurities, and enhance efficiency and sustainability. The research was presented to an audience of scientists, experts, and representatives from global pharmaceutical companies.
The article expresses pride in Al-Assadi's achievements and wishes him continued success.